Vogenx (NASDAQ:VOGX) Issues Quarterly Earnings Results

Vogenx (NASDAQ:VOGX) posted its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, Zacks reports.

Vogenx Stock Performance

Shares of Vogenx stock traded up $0.74 during trading hours on Thursday, reaching $34.13. 209,756 shares of the stock traded hands, compared to its average volume of 196,990. Vogenx has a one year low of $12.95 and a one year high of $36.00.

Wall Street Analyst Weigh In

VOGX has been the topic of a number of research analyst reports. Wall Street Zen raised Vogenx to a “hold” rating in a report on Saturday, August 22nd. JonesTrading started coverage on Vogenx in a report on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price objective for the company. Finally, WBB Securities assumed coverage on Vogenx in a research report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Strong Buy” and an average price target of $48.50.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.